Curis (CRIS) Capital Expenditures (2010 - 2022)

Curis' (CRIS) quarterly Capital Expenditures came in at $52000.0 in Q3 2022, down 85.27% on a QoQ basis from $353000.0 in Q2 2022.

Curis (CRIS) Capital Expenditures (2010 - 2022) Analysis & Trends

Curis (CRIS) has 12 years of Capital Expenditures data on file, last reported at $52000.0 in Q3 2022.

Quarterly Capital Expenditures changed N/A year-over-year to $52000.0 in Q3 2022, while the trailing twelve-month figure through Jun 2023 was $52000.0 (down 85.71% YoY) and the FY2022 annual result came in at $416000.0, changed N/A from the prior year.
Capital Expenditures retreated to $52000.0 in Q3 2022, from $353000.0 in the prior quarter.
In the past five years, Capital Expenditures ranged from a high of $353000.0 in Q2 2022 to a low of $8000.0 in Q3 2018.
A 4-year average of $121900.0 and a median of $64500.0 in 2018 frame the typical range for Capital Expenditures.
Annual changes were most pronounced in 2018 — Capital Expenditures tumbled 61.9% — and 2020, when it jumped 529.27%.
Tracing CRIS's Capital Expenditures over 4 years: stood at $8000.0 in 2018, then surged by 412.5% to $41000.0 in 2019, then slumped by 51.22% to $20000.0 in 2020, then jumped by 160.0% to $52000.0 in 2022.
The last three Capital Expenditures figures came in at $52000.0 (Q3 2022), $353000.0 (Q2 2022), and $11000.0 (Q1 2022), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Vertex Pharmaceuticals	140.00 Bn	132.14 Bn	2.84 Bn	112.20 Mn
2	Regeneron Pharmaceuticals	86.31 Bn	78.32 Bn	3.93 Bn	240.20 Mn
3	Argenx Se	65.24 Bn	60.06 Bn	1.37 Bn	-
4	Moderna	62.41 Bn	57.27 Bn	52.00 Mn	37.00 Mn
5	BeOne Medicines	42.25 Bn	37.15 Bn	1.53 Bn	25.02 Mn
6	Alnylam Pharmaceuticals	31.18 Bn	27.88 Bn	992.69 Mn	34.68 Mn
7	BioNTech SE	28.93 Bn	10.54 Bn	668.28 Mn	-73.57 Mn
8	Insmed	27.55 Bn	26.39 Bn	358.27 Mn	6.26 Mn
9	Royalty Pharma	27.28 Bn	26.44 Bn	-	251.02 Mn
10	Curis	3.49 Mn	-2.12 Mn	-	-

Download Data